Trial Profile
A Randomized, Parallel-Cohort Phase 1 Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute Graft Versus Host Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary) ; Methylprednisolone; Prednisone
- Indications Graft-versus-host disease
- Focus Adverse reactions; Proof of concept
- Sponsors Incyte Corporation
- 01 Aug 2022 Results deriving Plasma samples from (identification cohort; NCT02614612, n=25) and deriving data fromNCT03139604- a validation cohort; evaluating biomarker signature predicting complete response to itacitinib and corticosteroids in acute graft-versus-host disease, published in the British Journal of Haematology
- 10 Dec 2019 Results of proteomic analysis to identify potentially predictive biomarkers by using data from this study (n=25) presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 06 Mar 2019 Status changed from active, no longer recruiting to completed.